List view / Grid view

Bristol-Myers Squibb Company

news

Howie Mandel challenges people to learn the fibs and facts about atrial fibrillation and its associated increased stroke risk

28 October 2013 | By Bristol-Myers Squibb

“Fibs or Facts” educational program launches today to help raise up to $25,000 for National Stroke Association...

news

Promising phase IIb data on Clazakizumab in patients with moderate-to-severe rheumatoid arthritis to be presented

28 October 2013 | By Bristol-Myers Squibb Company

Clazakizumab is a humanized anti-IL-6 monoclonal antibody directed against the IL-6 cytokine rather than the receptor...

news

Promising phase IIb data on Clazakizumab in patients with moderate-to-severe Rheumatoid Arthritis to be presented

28 October 2013 | By Bristol-Myers Squibb Company

Clazakizumab is a humanized anti-IL-6 monoclonal antibody that is directed against the IL-6 cytokine...

news

Bristol-Myers Squibb to present range of new hepatitis C data at the 2013 American Association for the study of liver diseases (AASLD) annual meeting

1 October 2013 | By Bristol-Myers Squibb

Bristol-Myers Squibb Company (NYSE:BMY) announced today that 16 abstracts have been accepted for presentation at The Liver Meeting® 2013...

news

New Phase III data showed Dapagliflozin significantly reduced HbA1c compared to placebo

25 September 2013 | By Bristol-Myers Squibb Company

At 24 weeks in patients with Type 2 diabetes inadequately controlled with the combination of Metformin Plus Sulfonylurea...

news

Bristol-Myers Squibb Reports Results for Phase 3 Trial of Yervoy® (Ipilimumab) in Previously-Treated Castration-Resistant Prostate Cancer

12 September 2013 | By Bristol-Myers Squibb Company

Results from the Phase 3 randomized, double-blind clinical trial (Study 043)...

news

Subanalysis of Phase III ARISTOTLE trial of Eliquis® (apixaban) demonstrated consistent results versus warfarin in patients with NVAF with or without valvular heart disease

3 September 2013 | By Pfizer

Data show consistent results in reductions in stroke or systemic embolism, fewer major bleeding events, and reductions in all-cause death...

news

ONGLYZA® (saxagliptin) demonstrates no increased risk for cardiovascular death, heart attack or stroke in SAVOR cardiovascular outcomes trial

2 September 2013 | By AstraZeneca

SAVOR provides information on cardiovascular safety for Onglyza in the wake of past questions about cardiovascular safety of type 2 diabetes treatments...

news

New Eliquis® (apixaban) post-hoc subanalysis of the Phase III ARISTOTLE trial demonstrated that within 30 days of a procedure, stroke or systemic embolism and major bleeding were uncommon

31 August 2013 | By Pfizer

Results presented at the ESC Congress 2013...

news

Bristol-Myers Squibb and Samsung BioLogics announce biopharmaceutical manufacturing relationship

29 July 2013 | By Bristol-Myers Squibb Company

Bristol-Myers Squibb Company and Samsung BioLogics announced the companies have entered into a 10-year agreement...

news

US FDA acknowledges receipt of resubmission of the New Drug Application for investigational compound dapagliflozin for the treatment of type 2 diabetes

25 July 2013 | By AstraZeneca

The US FDA has acknowledged receipt of the NDA resubmission for investigational drug dapagliflozin for the treatment of adults with type 2 diabetes...

news

AstraZeneca and Bristol-Myers Squibb resubmit dapagliflozin New Drug Application for the treatment of type 2 diabetes in the U.S

25 July 2013 | By AstraZeneca

NDA for dapagliflozin resubmitted to FDA...

news

Bristol-Myers Squibb partners with the Centers for Disease Control Foundation

23 July 2013 | By Bristol-Myers Squibb Company

Joint effort supports early disease identification to connect at-risk patients to necessary care...

news

FDA accepts Eliquis® (apixaban) sNDA for review for prophylaxis of deep vein thrombosis following hip or knee replacement surgery

11 July 2013 | By Bristol-Myers Squibb Company

FDA accepted for review a sNDA for Eliquis®

news

FDA approves U.S. product labeling update for Sprycel®

20 June 2013 | By Bristol-Myers Squibb Company

Data added to Sprycel U.S. labeling are among the longest follow-up data of current CML treatment options...

Cookie	Description
cookielawinfo-checkbox-advertising-targeting	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics	This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance	This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID	This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged	This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.

Cookie	Description
cf_ob_info	This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob	This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only	This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush	This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db	This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC	This cookie is set by Youtube and is used to track the views of embedded videos.

Cookie	Description
bcookie	This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS	This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang	This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc	This cookie is set by LinkedIn and used for routing.
lissc	This cookie is set by LinkedIn share Buttons and ad tags.
vuid	We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId	This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule	This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session	This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues	This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga	This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat	This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid	This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.

Cookie	Description
advanced_ads_browser_width	This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions	This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info	This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer	This cookie is set by Advanced Ads and sets the referrer URL.
bscookie	This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE	This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr	This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory	This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE	This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.

Recommended

Bristol-Myers Squibb Company